Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia

Waldenstrom’s macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma with indolent course and prolonged disease course. The first-in-class Bruton’s tyrosine kinase inhibitor, ibrutinib, has shown significant activity and a distinct adverse event profile among both newly diagnosed and relapsed/r...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Blood Med
Main Authors: Papanota, Aristea-Maria, Ntanasis-Stathopoulos, Ioannis, Kastritis, Efstathios, Dimopoulos, Meletios A, Gavriatopoulou, Maria
Format: Artigo
Sprog:Inglês
Udgivet: Dove 2019
Fag:
Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717707/
https://ncbi.nlm.nih.gov/pubmed/31695539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S183997
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker